Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.

Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Cabral JMS, Ramos CA, Brenner MK, Mamonkin M.

Mol Ther. 2018 Oct 4. pii: S1525-0016(18)30490-8. doi: 10.1016/j.ymthe.2018.10.001. [Epub ahead of print]

PMID:
30391141
2.

Mice deficient in the mitochondrial branched-chain aminotransferase (BCATm) respond with delayed tumour growth to a challenge with EL-4 lymphoma.

Ananieva EA, Bostic JN, Torres AA, Glanz HR, McNitt SM, Brenner MK, Boyer MP, Addington AK, Hutson SM.

Br J Cancer. 2018 Oct;119(8):1009-1017. doi: 10.1038/s41416-018-0283-7. Epub 2018 Oct 15.

PMID:
30318512
3.

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G.

Mol Ther. 2018 Sep 13. pii: S1525-0016(18)30450-7. doi: 10.1016/j.ymthe.2018.09.009. [Epub ahead of print]

PMID:
30309819
4.

EBV/LMP-specific T cells maintain remissions of T and B cell EBV lymphomas after allogeneic bone marrow transplantation.

McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM.

Blood. 2018 Sep 27. pii: blood-2018-07-863654. doi: 10.1182/blood-2018-07-863654. [Epub ahead of print]

PMID:
30262660
5.

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A.

Clin Cancer Res. 2018 Aug 10. doi: 10.1158/1078-0432.CCR-18-0426. [Epub ahead of print]

PMID:
30097433
6.

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.

Sukumaran S, Watanabe N, Bajgain P, Raja K, Mohammed S, Fisher WE, Brenner MK, Leen AM, Vera JF.

Cancer Discov. 2018 Aug;8(8):972-987. doi: 10.1158/2159-8290.CD-17-1298. Epub 2018 Jun 7.

PMID:
29880586
7.

Onward and upward for immuno-oncology.

Brenner MK.

Chin Clin Oncol. 2018 Apr;7(2):18. doi: 10.21037/cco.2018.01.04. No abstract available.

8.

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.

Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF.

J Immunother Cancer. 2018 May 10;6(1):34. doi: 10.1186/s40425-018-0347-5.

9.

High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease.

Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, Carrum G, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, Brenner MK, Krance RA, Martinez CA.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1643-1650. doi: 10.1016/j.bbmt.2018.03.029. Epub 2018 Apr 6.

PMID:
29630926
10.

Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016.

Yanir AD, Martinez CA, Sasa G, Leung K, Gottschalk S, Omer B, Ahmed N, Hegde M, Eunji J, Liu H, Heslop HE, Brenner MK, Krance RA, Naik S.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1424-1431. doi: 10.1016/j.bbmt.2018.03.001. Epub 2018 Mar 14.

PMID:
29550628
11.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2018 Apr 10;36(11):1128-1139. doi: 10.1200/JCO.2017.74.3179. Epub 2018 Jan 9.

PMID:
29315015
12.

Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy.

Heslop HE, Brenner MK.

Mol Ther. 2018 Jan 3;26(1):1-2. doi: 10.1016/j.ymthe.2017.12.004. Epub 2017 Dec 20. No abstract available.

PMID:
29273500
13.

Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.

Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, Krenciute G, Orange JS, Brenner MK.

Cancer Immunol Res. 2018 Jan;6(1):47-58. doi: 10.1158/2326-6066.CIR-17-0126. Epub 2017 Oct 27.

14.

c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals.

Nishimura CD, Brenner DA, Mukherjee M, Hirsch RA, Ott L, Wu MF, Liu H, Dakhova O, Orange JS, Brenner MK, Lin CY, Arber C.

Blood. 2017 Dec 21;130(25):2739-2749. doi: 10.1182/blood-2017-02-769463. Epub 2017 Oct 27.

PMID:
29079582
15.

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.

Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, Cabral JMS, Rooney CM, Orange JS, Brenner MK, Mamonkin M.

Cell Rep. 2017 Oct 3;21(1):17-26. doi: 10.1016/j.celrep.2017.09.015.

16.

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.

Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M.

Mol Ther. 2017 Nov 1;25(11):2440-2451. doi: 10.1016/j.ymthe.2017.09.010. Epub 2017 Sep 14.

17.

Next Steps in the CAR Journey of a Thousand Miles.

Brenner MK.

Mol Ther. 2017 Oct 4;25(10):2226-2227. doi: 10.1016/j.ymthe.2017.09.013. Epub 2017 Sep 20. No abstract available.

18.

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM.

Cancer Discov. 2017 Nov;7(11):1238-1247. doi: 10.1158/2159-8290.CD-17-0538. Epub 2017 Aug 22.

19.

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B.

J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.

20.

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B.

J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.

21.

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.

Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B, Rouce RH, Lulla P, Rooney CM, Gottschalk S, Brenner MK.

Mol Ther. 2017 Sep 6;25(9):2202-2213. doi: 10.1016/j.ymthe.2017.05.024. Epub 2017 Jul 1.

22.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK.

Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.

23.

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M.

Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.

24.

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S.

JAMA Oncol. 2017 Aug 1;3(8):1094-1101. doi: 10.1001/jamaoncol.2017.0184.

25.

Fine-tuning the CAR spacer improves T-cell potency.

Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF.

Oncoimmunology. 2016 Nov 8;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.

26.

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF.

Mol Ther. 2017 Jan 4;25(1):249-258. doi: 10.1016/j.ymthe.2016.10.016. Epub 2017 Jan 4.

27.

Immunotherapy against cancer-related viruses.

Tashiro H, Brenner MK.

Cell Res. 2017 Jan;27(1):59-73. doi: 10.1038/cr.2016.153. Epub 2016 Dec 23. Review.

28.

Improving the safety of T-Cell therapies using an inducible caspase-9 gene.

Zhou X, Brenner MK.

Exp Hematol. 2016 Nov;44(11):1013-1019. doi: 10.1016/j.exphem.2016.07.011. Epub 2016 Jul 26. Review.

29.

Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch.

Yagyu S, Hoyos V, Del Bufalo F, Brenner MK.

Mol Ther Methods Clin Dev. 2016 Mar 9;3:16003. doi: 10.1038/mtm.2016.3. eCollection 2016.

30.

A whole blood model of thrombocytopenia that controls platelet count and hematocrit.

Bercovitz RS, Brenner MK, Newman DK.

Ann Hematol. 2016 Oct;95(11):1887-94. doi: 10.1007/s00277-016-2777-9. Epub 2016 Aug 12.

31.

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N.

J Clin Invest. 2016 Aug 1;126(8):3036-52. doi: 10.1172/JCI83416. Epub 2016 Jul 18.

32.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.

33.

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP.

Mol Ther. 2016 Jun;24(6):1135-1149. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.

34.

3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus.

Del Bufalo F, Manzo T, Hoyos V, Yagyu S, Caruana I, Jacot J, Benavides O, Rosen D, Brenner MK.

Biomaterials. 2016 Apr;84:76-85. doi: 10.1016/j.biomaterials.2016.01.030. Epub 2016 Jan 20.

PMID:
26826297
35.

Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.

Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK.

Mol Ther. 2016 Apr;24(4):823-31. doi: 10.1038/mt.2015.234. Epub 2015 Dec 28.

36.

Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch.

Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G.

Mol Ther. 2016 Apr;24(4):736-45. doi: 10.1038/mt.2015.217. Epub 2015 Dec 7.

37.

Effect of 22q11.2 deletion on bleeding and transfusion utilization in children with congenital heart disease undergoing cardiac surgery.

Brenner MK, Clarke S, Mahnke DK, Simpson P, Bercovitz RS, Tomita-Mitchell A, Mitchell ME, Newman DK.

Pediatr Res. 2016 Feb;79(2):318-24. doi: 10.1038/pr.2015.216. Epub 2015 Oct 22.

38.

CAR-T Cell Therapy for Lymphoma.

Ramos CA, Heslop HE, Brenner MK.

Annu Rev Med. 2016;67:165-83. doi: 10.1146/annurev-med-051914-021702. Epub 2015 Aug 26. Review.

39.

A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.

Ando M, Nishimura T, Yamazaki S, Yamaguchi T, Kawana-Tachikawa A, Hayama T, Nakauchi Y, Ando J, Ota Y, Takahashi S, Nishimura K, Ohtaka M, Nakanishi M, Miles JJ, Burrows SR, Brenner MK, Nakauchi H.

Stem Cell Reports. 2015 Oct 13;5(4):597-608. doi: 10.1016/j.stemcr.2015.07.011. Epub 2015 Aug 28.

40.

Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers.

Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK.

Mol Ther. 2015 Sep;23(9):1497-506. doi: 10.1038/mt.2015.110. Epub 2015 Jun 18.

41.

iCaspase 9 Suicide Gene System.

Zhou X, Di Stasi A, Brenner MK.

Methods Mol Biol. 2015;1317:87-105. doi: 10.1007/978-1-4939-2727-2_6.

42.

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.

Mamonkin M, Rouce RH, Tashiro H, Brenner MK.

Blood. 2015 Aug 20;126(8):983-92. doi: 10.1182/blood-2015-02-629527. Epub 2015 Jun 8.

43.

An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells.

Yagyu S, Hoyos V, Del Bufalo F, Brenner MK.

Mol Ther. 2015 Sep;23(9):1475-85. doi: 10.1038/mt.2015.100. Epub 2015 May 29.

44.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK.

Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.

45.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA.

Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4.

46.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S.

J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23.

47.

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.

Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM.

J Immunother Cancer. 2015 Feb 18;3:5. doi: 10.1186/s40425-015-0049-1. eCollection 2015.

48.

A question of reproducibility.

Frederickson RM, Brenner MK.

Mol Ther. 2014 Dec;22(12):2015. doi: 10.1038/mt.2014.211. No abstract available.

49.

Where is the good in goodbye?

Brenner MK.

Mol Ther. 2014 Nov;22(11):1873-4. doi: 10.1038/mt.2014.184. No abstract available.

50.

Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.

Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK, Bouchier-Hayes L.

Cancer Gene Ther. 2014 Nov;21(11):472-482. doi: 10.1038/cgt.2014.53. Epub 2014 Oct 17.

Supplemental Content

Loading ...
Support Center